Blood cancer market will not be able to sustain oversaturated cell therapy pipeline

Cell therapies are among the most researched treatment types for blood cancer and the product pipeline is oversaturated, with over 800 products currently in development for just five major blood cancers.

As a result, data and analytics company GlobalData warns that the blood cancer market will not be able to sustain this many products, even if they all meet regulatory requirements.

GlobalData’s oncology and hematology analyst Sakis Paliouras, comments: “Cell therapies have seen some strong successes in the oncology market, with Gilead’s Yescarta and Novartis’ Kymriah paving the way for other developers to build upon the success of their chimeric antigen receptor T-cells (CAR-T) cells. However, this success has brought about an abundance of products in development. Oncology is unlike other therapy areas such as cardiology or immunology, where the commercialization of a large number of products with similar attributes is the norm. If all of the in-development drugs for blood cancer got the go-ahead from the FDA, competition would be much too fierce.”